Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

Benzinga Newsdesk www.benzinga.com Positive 83.3%

Neg 0% Neu 0% Pos 83.3%

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.